Zhitong Finance App News, Fosun Pharmaceuticals (02196.HK) issued an announcement. On December 9, 2025, the company's holding subsidiaries, Yakyu Pharmaceuticals, Fosun Pharmaceutical Industry, and Pfizer jointly signed a “License Agreement”. (which mainly includes) Pharmacogon-like (GLP-1R) agonists (including YP05002) for oral small molecule glucagon-like peptide-1 () agonists (including YP05002) and products containing this active ingredient were granted to Pfizer in the licensed region (that is, worldwide) and fields (treatment, diagnosis and prevention of all indications in humans and animals) Right to transformation ; With regard to this license, Yaoyou Pharmaceutical will be entitled to receive (including) a non-refundable down payment of 150 million US dollars and development milestone payments of up to 350 million US dollars based on clinical and commercialization progress of the licensed product.

Zhitong Finance App News, Fosun Pharmaceuticals (02196.HK) issued an announcement. On December 9, 2025, the company's holding subsidiaries, Yakyu Pharmaceuticals, Fosun Pharmaceutical Industry, and Pfizer jointly signed a “License Agreement”. (which mainly includes) Pharmacogon-like (GLP-1R) agonists (including YP05002) for oral small molecule glucagon-like peptide-1 () agonists (including YP05002) and products containing this active ingredient were granted to Pfizer in the licensed region (that is, worldwide) and fields (treatment, diagnosis and prevention of all indications in humans and animals) Right to transformation ; With regard to this license, Yaoyou Pharmaceutical will be entitled to receive (including) a non-refundable down payment of 150 million US dollars and development milestone payments of up to 350 million US dollars based on clinical and commercialization progress of the licensed product.